



**HAL**  
open science

# Circulating Aflatoxin B1-Related TP53 Mutation Detected by Digital PCR in Tunisian Patients with and Without Hepatocellular Carcinoma

Agnès Marchio, Ines Dhifallah, Olfa Bahri, Pascal Pineau

► **To cite this version:**

Agnès Marchio, Ines Dhifallah, Olfa Bahri, Pascal Pineau. Circulating Aflatoxin B1-Related TP53 Mutation Detected by Digital PCR in Tunisian Patients with and Without Hepatocellular Carcinoma. Hepatitis Monthly, 2019, 19 (3), 10.5812/hepatmon.85775 . pasteur-02611953

**HAL Id: pasteur-02611953**

**<https://pasteur.hal.science/pasteur-02611953>**

Submitted on 18 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



# Circulating Aflatoxin B1-Related *TP53* Mutation Detected by Digital PCR in Tunisian Patients with and Without Hepatocellular Carcinoma

Agnes Marchio #1, Ines Dhifallah #2, Olfa Bahri <sup>3</sup> and Pascal Pineau #1,\*

<sup>1</sup>Unite "Organization nucleaire et Oncogenese", INSERM U993, Institut Pasteur, Paris, France

<sup>2</sup>Laboratory of Clinical Virology, Pasteur Institute of Tunis, Faculty of Sciences of Bizerte, University of Carthage, Tunis, Tunisia

<sup>3</sup>Laboratory of Clinical Virology, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis, Tunisia

\*Corresponding author: Unite "Organization nucleaire et Oncogenese", INSERM U993, Institut Pasteur, Paris, France. Email: pascal.pineau@pasteur.fr

#These authors are contributed equally as the first author.

Received 2018 October 26; Revised 2019 January 15; Accepted 2019 February 08.

## Abstract

**Background:** In the recent years, hepatocellular carcinoma (HCC) has become one of the first causes of cancer mortality in humans. Among the issues explaining this appalling situation the lack of early biomarkers occupies a prominent position. In patients with tumors, free circulating DNA originating from tumor cells represents a promising material for the early detection of the disease. In HCC, two mutations, R249S on *TP53* and -124C>T in *TERT* promoter, are potentially present in large subsets of patients and could be considered as good candidate biomarkers. Tunisia is a subtropical country where persistent infections with hepatitis virus represent a significant burden of diseases and food contamination with mycotoxins has been consistently detected.

**Methods:** In a pilot study, using the droplet digital PCR (ddPCR) technique, blood samples from 47 patients with HCC and 51 control individuals were evaluated for the presence of the *TP53* or *TERT* mutants in the bloodstream.

**Results:** We observed that 19.1% and 14.9% of the patients with HCC were carrying *TP53* or *TERT* mutants, while 47.1% and 5.8% of controls were positive for the same biomarkers ( $P = 0.005$  and  $P = 0.18$ , ns). Most (66.6%) HCC patients with *TP53* R49S were coming from the region of Nabeul (North East).

**Conclusions:** This preliminary analysis indicates that droplet digital might be useful for the diagnosis of HCC or screening high-risk subjects in the North African context. In addition, our results confirm previous data obtained by foodstuffs analyses suggesting that a sizeable proportion of the middle-aged Tunisian population is or has been significantly exposed to aflatoxin B1. Larger studies are now mandatory to confirm and refine these preliminary data.

**Keywords:** Hepatocellular Carcinoma, Aflatoxin B1, *TP53*, *TERT*, Mutations, Droplet Digital

## 1. Background

After lung and breast cancers, hepatocellular carcinoma (HCC) is currently the third cause of cancer mortality in humans. The prognosis of the disease remains particularly dismal with an overall mortality that corresponds to 95% of its incidence (1). According to the World Health Organization, in the great Middle East and North Africa (MENA) region severe liver diseases, including HCC, are among the pathologies that have grown in prevalence during the last decades (2).

In Tunisia, several HCC risk factors are significantly prevalent in the general population. Indeed, persistent infections with hepatitis B (HBV) and C viruses (HCV) represent important public health issues for the country with historically high endemic levels of HBV carriage in Southern Tunisia, while HCV has presumably spread more re-

cently essentially through iatrogenic transmission around selected urban centers of northern regions (3, 4). More recently, the large increase in the non-alcoholic fatty liver disease (NAFLD) cases has been identified as a significant contributor to an insidious degradation of liver health in Tunisia (5).

Besides infectious and metabolic risk factors, environmental agents such as harmful mycotoxins have been suspected for decades to play a significant role in the epidemiology of liver diseases observed in Tunisia (6). Most noticeably, Tunisian researchers have consistently isolated aflatoxin B1 (AFB1), a major liver carcinogen, in local food components of vegetal (maize, sorghum, nuts) or animal (milk) origins (7, 8).

Furthermore, a few years ago, Public Health authorities issued a warning regarding the consumption of AFB1-

contaminated nuts from Aleppo pine (*zgougou* in local language, *Pinus halepensis*), a major component of some of the most popular Tunisian pastries. Despite the considerable concerns generated by this alarming information, no molecular data measured the consequences of AFB1 exposure in patients with liver diseases. For this reason, we set out to explore the free circulating DNA (fcDNA) from Tunisian patients with HCC for the presence of the AFB1-induced *TP53* mutation at codon 249 (ARG249SER) (9). This G>T mutation affects codon 747 of *TP53* and has been consistently associated with AFB1 exposure in all geo-epidemiological backgrounds tested so far (10, 11). In addition, we looked for the presence of the *TERT* promoter mutation at nucleotide-124 that is considered as the most prevalent somatic alteration in human HCC (12).

To increase the probability of detecting minute amounts of mutants, we decided to use the droplet digital PCR (ddPCR) technique. ddPCR technique allows the independent amplification of microcompartments and their subsequent one-by-one analysis in a microfluidic device through the partitioning of reagents in 15,000 - 20,000 pico-droplets. Although its use is not recommended in all circumstances, it has been recurrently shown in the recent years either for cancer mutations monitoring, infectious agent detection, or prenatal diagnosis that ddPCR is more sensitive than traditional quantitative real-time PCR to detect targets that represent only a small fraction of a much larger and more complex population of DNA molecules (13-17).

## 2. Methods

### 2.1. Patients

This case-control study was performed among HCC patients referred to Gastroenterology departments of La Rabta (Tunis) and Tahar Maamouri hospitals (Nabeul) and the Department of Surgery of Mongi Slim Hospital (La Marsa, Tunis). The diagnosis of 47 HCC cases was based on clinical symptoms and the status of the non-tumor liver, presence of a liver mass at ultrasound, the serological context, hematoxyllin-eosin staining of tissue section and measurement of serum alpha-fetoprotein (AFP) levels. Cases were individually 1:1 paired-matched by sex and age ( $\pm 5$  years) with control subjects consecutively selected and represented by patients with or without serological signs of chronic liver infection presenting to the same medical departments during the same period. Investigations were approved by the Ethics Committee of Tunisian

Ministry of Health. An informed consent was obtained for each patient enrolled in the study.

### 2.2. DNA Extraction and Quantification

Sera were collected, aliquoted and stored at  $-80^{\circ}\text{C}$ . Circulating free DNA was extracted from a mean volume of 600  $\mu\text{L}$  of serum. Briefly, sera were digested overnight at  $37^{\circ}\text{C}$  under mild agitation in a buffer corresponding to a final concentration of 10 mM EDTA, 2% sodium dodecyl sulfate (SDS) and 0.1  $\mu\text{g}/\text{mL}$  proteinase K (Eurobio, Les Ulis, France). Samples were then successively submitted to a phenol pH 8.0 and to chloroform-isoamylalcohol extractions. Aqueous phase was precipitated by ethanol (2.5 volumes) overnight at  $-80^{\circ}\text{C}$  in the presence of 0.1 of 3 M sodium acetate, pH 6.0 and T40 dextran (2  $\mu\text{L}$ ). After 60 min/14000 rpm centrifugation, DNA pellet was rinsed in 70% ethanol at room temperature, solubilized in TE pH 8.0 buffer and quantified by Qubit dsDNA HS assay kit (Life Technologies, Villebon, France).

### 2.3. Circulating Mutations Detection

Amplifiability of cfDNA was first checked on a single copy nuclear gene (*MGEA5*, meningioma expressed antigen 5, sense primer, CCCGTACAAAGGAAGATCCA, reverse primer, ATTTGTACCAGGTGGCAAGG) by a standard quantitative real-time PCR. Samples that yielded satisfying results were further studied. The assays employed were a TaqMan™ SNP Genotyping Assay (C-60493487-10, Life technologies, Villebon, France) for *TP53* R249S and the PrimePCR™ ddPCR™ Copy Number Assay (dHsaCP1000100, Bio-Rad, Marnes-la-Coquette, France). Droplet digital PCR reactions were performed on the QX100 system (Bio-Rad, Hercules, CA, USA). Reaction mixture consisted of 10  $\mu\text{L}$  ddPCR Supermix (Bio-Rad, Marnes-la-Coquette, France), 1.6X TaqMan™ SNP Genotyping Assay (C-60493487-10, Life technologies, Villebon, France), and 3  $\mu\text{L}$  of cfDNA isolated from plasma samples in a final volume of 20  $\mu\text{L}$  was mixed with 70  $\mu\text{L}$  of droplet generation oil (Bio-Rad) and partitioned into approximately 20,000 droplets in the QX100 droplet generator (Bio-Rad). The droplets generated from each sample were transferred to a 96-well plate and PCR amplification was conducted in an iCycler PCR instrument (Bio-Rad) with the following conditions:  $95^{\circ}\text{C}$  for 10 minutes, 40 cycles of  $94^{\circ}\text{C}$  for 30 sec with a ramping of  $2^{\circ}/\text{sec}$ ,  $59^{\circ}\text{C}$  for 1 minutes with a ramping of  $2^{\circ}/\text{sec}$ , followed by  $98^{\circ}\text{C}$  for 5 minutes and a hold at  $4^{\circ}\text{C}$ . After amplification, the 96-well plate was loaded onto the QX100 droplet reader (Bio-Rad) that automatically measures the fluorescence intensity in individual droplets. The generated data were subsequently analyzed with QuantaSoft™ software (Bio-Rad)

based on positive and negative droplet populations. For *TP53*, genomic DNA from the PLC/PRF5 HCC cell line that harbors the R249S mutation was included as a positive control in each experiment, while a genomic DNA from a tumor mutated in -124 of *TERT* promoter was used as positive control. The genomic DNA extracted from peripheral blood mononuclear cells of a subject without any mutants was used as negative control in all the experiments.

Samples positive for *TP53* R249S or *TERT* -124C>T were tested at least twice in two independent runs, while samples negative for mutants but yielding more than 1000 droplets for the control locus *MGEA5* where tested once and scored as negative. Samples negative for mutants and displaying less than 1000 droplets positive for control locus were tested at least twice in two independent runs. Samples discarded from the analysis did not generate any fluorescent droplets (one sample for patients and controls) or a sufficient merged number of droplets positive for the reference gene *MGEA5*. Samples were considered positive for *TP53* R249S or *TERT* -124 c>t when at least two droplets were found positive for mutant alleles in two independent droplet digital PCR runs.

#### 2.4. Statistical Analyses

Statistical analyses were performed using Prism 6.0 statistical package. Numerical variables were summarized by their median, mean and range according to their types of distribution (normal or not). They were compared either by a Student's *t*-test or by Mann-Whitney test as appropriate. Categorical variables were summarized as frequencies that were compared by Fisher's exact test. All the tests were two-sided and the level of significance was set at  $P < 0.05$ .

### 3. Results

The clinico-biological characteristics of the patients are described in [Table 1](#). Patients and controls were essentially different in terms of the seroprevalence of anti-HCV and non-infectious risk factors for HCC. Circulating free DNA (cfDNA) concentrations in sera were similar in patients and controls ( $\sim 480$  ng/mL).

From the initial series, 47 and 51 serum samples collected from patients with HCC and from controls yielded a number of droplets suitable for further interpretation of the mutants searched. For *TERT* mutants, a median of 1950 droplets (range: 610 - 23761) was analyzed. There was no significant difference in droplet numbers between HCC and controls. We found that seven patients with HCC harbored

a -124 C>T *TERT* mutation ( $n = 7/47$ , 14.8%), whereas three control participants were carrying this mutation ( $n = 3/51$ , 5.8%, OR = 2.7, 95% CI: 0.58 - 7.6,  $P = 0.18$ , ns, [Figure 1A](#)). The ratio of *TERT*-mutated positive droplets for patients with HCC ranged from  $1.0E-03$  to  $8.3E-03$  and the corresponding value of the control subject was similar ( $4.3E-03$ ).

Patients with *TERT* mutations were marginally different from the rest of the series. All of them were presenting with antecedents of persistent infection with a hepatitis virus. Indeed, six of them were seropositive for anti-HCV, and the last one was carrier of HBV surface antigen (HBsAg). None of them was nonBnonC, while a sizeable proportion of the patients with wild-type *TERT* were (0.0% vs. 28.4%;  $P = 0.166$ , ns). Liver injury tends to be more important in *TERT*-mutated patients as shown by alanine aminotransferase levels (110 vs. 63 IU/mL;  $P = 0.072$ , ns). All the patients with *TERT* mutant had a cirrhotic liver, a situation in keeping with the pathophysiology of this molecular alteration that appears mostly in regenerative nodules in strongly fibrotic liver tissues. In three patients presenting this mutant, AFP levels were below the common diagnostic threshold for HCC ( $< 300$  ng/mL) suggesting that search for *TERT* mutants might be useful to complement diagnostic armamentum for some patients with HCC. The size of the tumors in *TERT*-positive patients tended to be larger than those with the wild-type version ([Figure 2A](#)). Patients with *TERT* mutants were coming from only three regions from Northern Tunisia (Jendouba, Nabeul and Tunis governorates).

Concerning the circulating *TP53* mutants, the situation was drastically different. A subset of nine patients with HCC ( $n = 9/47$ , 19.1%) was positive for *TP53* R249S mutant, whereas in controls this rate was surprisingly higher ( $n = 24/51$ , 47.0%;  $P = 0.005$ ; [Figure 1B](#)). In HCC patients,  $6.0E-04$  to 2.7% of the droplets were positive (analyzed droplet median = 2009, range: 606 - 11050), whereas in controls between  $6.0E-04$  and 4.1% were loaded with a mutant version of codon 249 (median = 2401, range: 627 - 20728;  $P = 0.23$ , ns). Two patients with R249S were also carrying *TERT*-124 C>T, whereas it was also the case for a single control subject.

Clinical features of the patients with the circulating R249S were not drastically different from those observed in the remaining cohort. Among the differences, though, none of them was affected with type 2 diabetes, whereas it was the case in 36.8% of the R249S-negative patients ( $P = 0.041$ ). Interestingly, tumor sizes of mutant carriers were, albeit non-significantly, rather small ( $25.8 \pm 4.8$  mm vs.  $43.0 \pm 5.1$  mm;  $P = 0.082$ , ns; [Figure 2B](#)) suggesting that

**Table 1.** Demographic, Clinical and Biological Features of Patients with Hepatocellular Carcinoma and Controls


| Clinico-Biological Features              | HCC, N = 47  | Controls, N = 51 | P Value   |
|--|--------------|------------------|-----------|
| <b>Age</b>                               | 62.2 ± 9.3   | 63.7 ± 11.5      | ns        |
| <b>Sex ratio</b>                         | 0.95 (23:24) | 0.82 (23:28)     | ns        |
| <b>Serological features, %</b>           |              |                  |           |
| HBsAg                                    | 23.4         | 9.8              | 0.10 (ns) |
| Anti-HCV                                 | 53.2         | 5.9              | 2.3E-07   |
| Anti-HBc                                 | 55.3         | 37.2             | 0.10 (ns) |
| Anti-HBs                                 | 19.1         | 35.3             | 0.11 (ns) |
| HBeAg                                    | 8.5          | -                | -         |
| Anti-HBe                                 | 38.3         | -                | -         |
| Anti-Delta                               | 2.1          | 0.0              | ns        |
| NonB-nonC                                | 25.5         | 84.3             | 4.0E-09   |
| <b>Other risk factors, %</b>             |              |                  |           |
| Tobacco consumption                      | 34.7         | 13.9             | 0.02      |
| Alcohol intake                           | 24.4         | 0.0              | 4.8E-04   |
| Type 2 diabetes                          | 31.1         | 6.6              | 0.002     |
| <b>AFP, ng/mL, %</b>                     |              |                  |           |
| > 300                                    | 33.3         | -                | -         |
| 10 - 300                                 | 38.4         | -                | -         |
| < 10                                     | 28.2         | -                | -         |
| <b>Liver cirrhosis</b>                   | 76.5         | -                | -         |
| <b>Child-pugh stage, %</b>               |              |                  |           |
| A  | 35           | -                | -         |
| B  | 56           | -                | -         |
| C  | 9            | -                | -         |
| <b>Circulating free DNA, ng/mL</b>       | 484.2 ± 81.8 | 489.1 ± 45.7     | ns        |
| <b>Prothrombin time, %</b>               | 68.2 ± 13.6  | -                | -         |
| <b>Platelets, /mL</b>                    | 115 ± 66     | -                | -         |
| <b>Tumor diameter, main nodule, mm</b>   | 41 ± 29      | -                | -         |
| <b>Multiple nodules, %</b>               | 52.2         | -                | -         |
| <b>Aspartate aminotransferase, IU/mL</b> | 82 ± 61      | 51 ± 59          | 0.018     |
| <b>Alanine aminotransferase, IU/mL</b>   | 70 ± 58      | 59 ± 80          | 0.47 (ns) |
| <b>γ-Glutamyl transpeptidase, IU/mL</b>  | 130 ± 140    | 28 ± 32          | 0.0069    |
| <b>Alkaline phosphatases, IU/mL</b>      | 377 ± 787    | 153 ± 134        | 0.10 (ns) |
| <b>Total bilirubin, mg/L</b>             | 31 ± 35      | 26 ± 50          | ns        |

Abbreviations: AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; HCV, hepatitis C viruses.


ddPCR detection of this mutation might take place early in tumor surveillance. The most remarkable feature of the TP53 R249S-positive HCC patients was their origin as six out of nine (66.6%) were coming from Nabeul governorate, whereas 2 out of 38 R249S-negative patients were coming

from this governorate (5.2%;  $P = 1.4E-04$ ,  $OR = 32.3$ , 95%  $CI = 3.9 - 468.0$ ; [Figure 2C](#)). This observation suggests that the impact of AFB1 on liver health in Tunisia might be heavier in the northern coastal region of Nabeul ([Figure 2D](#)).

Control subjects positive for R249S mutations were not



**Figure 1.** A, Prevalence of *TERT*-124 C>T mutants in patients with HCC (n = 47) and in control subjects (n = 51). B, Prevalence of *TP53* R249S mutants in patients with HCC (n = 47) and in control subjects (n = 51).



**Figure 2.** A, Tumor diameter in mm of the patients with detectable circulating *TERT* mutants and in those without detectable mutants. B, Tumor diameter in mm of the patients with detectable circulating *TP53* mutants and in those without detectable mutants. C, Proportion of patients originating from Nabeul and the rest of country with detectable circulating *TP53* mutants. D, Location of Nabeul governorate in Tunisia.

different from other controls in any of the available demographic, clinical or biological features. Overall, our analysis indicates that an important proportion of the Tunisian population, either affected by a serious liver disease or with an apparently healthy liver, is exposed to the mutagenic activity of AFB1. Controls with R249S were coming

from eight different governorates with Tunis (n = 9) and Jendouba, (n = 6) as main geographical origins.

#### 4. Discussion

Due to an historically large diffusion of some of its main risk factors (e.g., HBV and alcohol intake) and the re-

cent spread of novel etiologies (e.g., HCV and fatty liver diseases), HCC incidence has progressed in most regions of the world in the last decades and so did the corresponding mortality. In the immense majority of cases, HCC is secondary to a protracted liver disease that frequently progressed to cirrhosis explaining why in most cases patients present to tertiary healthcare institutions with an already significantly altered personal clinical status. The prognosis of the disease is thus overwhelmingly poor, especially in low- and middle-income countries where the surveillance system is usually not adequate. Implementation of new biomarkers capable that can be combined with alpha-fetoprotein (AFP) detection to diagnose early forms of HCC is thus of paramount importance to improve the rate of cure or to reasonably extend the median survival rate of patients with HCC. High-throughput sequencing or new forms of PCR techniques currently provide the possibility to explore the blood for the presence of rare molecules shed by tumor cells in an approach conveniently designated as liquid biopsy.

In the great MENA region defined by the World Health Organization, the overall prevalence of chronic infections with hepatitis B (HBV) or C (HCV) viruses ranges around 2% -3% but reaches 15% -20% in Egypt (i.e., between 22 - 26 million individuals are concerned) (18-20). In addition, MENA is known as one of the regions (with the United States of America) with the highest rates of overweight/obesity, metabolic syndrome, and type-2 diabetes (T2D) (21). Indeed, metabolic disorders are currently affecting MENA populations as early as infancy or childhood, a situation predicted to have deleterious health consequences for the future grown-up generations. Dysmetabolic conditions have emerged recently as a major cause of morbidity for the liver and they represent important risk factors for terminal diseases such as cirrhosis and HCC (22, 23). The outcomes of such worrying epidemiological situation are that liver cirrhosis represents currently the 6th cause of death in the region and HCC incidence had massively increased in the past decades (2). In Tunisia, itself, with a little bit more than 110 cases of HCC per year, the toll taken by primary liver cancer is thus considered as relatively mild according to GLOBOCAN 2012 (1). However, it has been frequently suggested and recently substantiated that in low- and middle-income countries (LMICs) the incidence of HCC is probably significantly underestimated (24). In addition, in Tunisia, the median survival time of patients diagnosed with HCC is low as it barely exceeds 6 months (25).

Recent works have shown that -124C>T mutation in *TERT* promoter represents undoubtedly a very promising

DNA marker for early HCC detection (12). In the present series, this mutant was found in almost 15% of patients but also in 6% of controls, thereby precluding any significant association with liver tumorigenesis due to the small size of the tested groups. However, in accordance with data from whole genome sequencing, we observed that the *TERT* point mutation was more abundant in HCV-infected patients (22.2%) than in HBV-infected cases (10.0%) or uninfected patients (0.0%) (26). In HBV-infected patients, a significant proportion of *TERT* alterations are actually provided by HBV DNA integrations in the gene promoter making point mutant no longer necessary for tumorigenesis. We consider, therefore, that -124C>T mutant still represents a promising biomarker in the monitoring of cirrhotic patients at risk for HCC, or the diagnosis of HCC in case of ambiguous imaging assessment of the liver nodule.

Global climate warming is suspected to extend the areas where aflatoxin-producing strains of *Aspergillus* will be distributed (27). As an example, sterigmatocystin, a precursor metabolite of aflatoxin B<sub>1</sub>, has been retrieved recently in grains from Norway (28). The long-time proven presence of AFB<sub>1</sub> in a significant proportion of staple food consumed in Tunisia joint to the possibility to detect its mutagenic consequences in the blood of patients with HCC make Tunisians an attractive target to test the presence of tumor-associated alterations in the blood (7, 8, 29-34). The present work confirms the warning issued for decades by environmental scientists and proved that Tunisians are or have been recently exposed to the mutagenic activity of AFB<sub>1</sub>.

Our data suggest that Aleppo pine nuts are probably not the principal culprit in this situation. This nut is produced mostly in the central mountains in the region of Kasserine and consumed throughout the country, whereas *TP53* R249S is found mostly in patients from Nabeul governorate on the north eastern coast of Tunisia. The Nabeul governorate is a major agricultural region in Tunisia with large segments of irrigated cultures dedicated to the production of oranges (*Citrus reticulata*) or chili pepper (*Capiscum*), the latter used in the national condiment *Harissa*. The spoilage of oranges (i.e., fruits and juice) or chili pepper with *Aspergillus* and their subsequent contamination by aflatoxin have been already described (35, 36). Our results should represent a strong incentive to conduct field studies in Nabeul governorate and elsewhere in the country with the aim of finding the eventual source of AFB<sub>1</sub>.

Among the questions raised by our analyses is the counter-intuitively higher prevalence of *TP53* R249S mutants in controls than in patients with HCC. A logical expla-

nation could be that the number target cells (i.e., hepatocytes) is much higher in healthy subjects than in patients with HCC who are generally affected with liver cirrhosis. In such circumstances, the parenchyma is replaced by fibrotic scars that lead on the long term to liver failure characterized by a number of hepatocytes insufficient to produce enough clotting factors or to detoxify ammonia.

In addition, liver cirrhosis is associated with a reduction of blood flow in the liver materialized by collateral venous circulation. Taken together, these phenomena might both contribute to reduction in the number of liver targets for AFB1 and the access of the mycotoxin to its primary site of action. In our opinion, this pathophysiological process might explain the higher prevalence of TP53 R249S in subjects with a healthy liver when compared to patients with a terminal liver disease. Two reports from Egypt have explored the presence of TP53 R249S mutants in cfDNA of patients with HCC. Hosny et al. (37) found a higher prevalence of mutation carriers in patients without HCC but with HBV infection (16.7% vs. 1.3%), whereas El-Din et al. (38) detected more mutants in patients with HCC than in controls with liver cirrhosis (15.0% vs. 0.0%). Overall, these results are consistent with our hypothesis that considers cirrhotic livers as cell-poor tissues unfavorable to the constant release of the R249S mutation and to its subsequent detection in plasma. In keeping with this hypothesis, Traore et al. analyzed a population of HBV-infected subjects in Bamako (Mali, South of the Sahara) and found more than 40 R249S copies/mL of plasma in 60% of cases (39). The use of ddPCR as a quantitative technique might, however, enable us to sort-out in the future between an ongoing clonal cell proliferation indicative of a tumor process and the presence in the blood of genomes from isolated cells killed directly either by aflatoxin B1 or by immune cells chasing for neoantigens generated by AFB1 mutagenesis.

As suggested previously, it is highly plausible that in absence of concomitant persistent infection with a hepatitis virus, control subjects with healthy liver will not develop HCC despite the presence of R249S mutant in their sera (37). In these populations, TP53 R249S is thus not a *bona fide* tumor biomarker but merely a marker of exposure to AFB1. Beyond the issue of HCC that is supposedly of minor concern for public health in Tunisia, our work implies that AFB1 might produce in Tunisia its deleterious effects outside the liver on various segments of the population. It is well-known that besides its widely advertised mutagenic activity, AFB1 is endowed with multiple toxicities that affect most notably the growth of children and the immune system of the subjects exposed (40-42). These potential extra-

hepatic consequences of AFB1 activity on the Tunisian population might thus represent an ominous challenge for public health.

Our study suffers from an important limitation, that is, the small number of patients investigated. This shortcoming prevents any firm and definitive conclusion concerning the true distribution and in vivo impact of AFB1 contamination on the Tunisian population. Our work is, however, seminal as it is the first to be conducted on that field in the whole Maghrib region that consists of more than 86 million habitants. It should be therefore considered as a whistleblowing study aiming to stimulate more ambitious research programs and to attract the attention of public health stakeholders.

In conclusion, our study indicates that droplet digital PCR might represent a useful tool to complement the current procedures of HCC diagnosis. In addition, our data indicates that this technique could be useful when implemented in public health research. In the present case, it seems that middle-aged Tunisians are heavily exposed to the mutagenic activity of AFB1 as previously suggested by environmental and food scientists (6). Urgent initiatives are now necessary to confirm our data and eventually reduce the impact of AFB1 on Tunisians, as its deleterious activity might extend well beyond the carcinogenic risk, and inter alia, impacts with unforeseeable longer-term consequences the health of the younger strata of the population.

## Acknowledgments

We express our gratitude to Marion Benabou and Thomas Bourgeron (Unité de Génétique humaine et fonctions cognitives, Institut Pasteur, Paris) for their help in the use of the droplet digital PCR machine. We feel indebted to Prof. Anne Dejean for her constant support in the lab. This work was supported by the French Ligue Nationale Contre le Cancer (Equipe Labélisée d'Anne Dejean) and the Tunisian secretariat for Scientific Research and Technology (SERST, contract: LR1SP09).

## Footnotes

**Authors' Contribution:** Agnes Marchio and Ines Dhifallah performed the experiments. Ines Dhifallah and Olfa Bahri collected samples and clinical annotations. Olfa Bahri and Pascal Pineau designed the study. Pascal Pineau drafted the manuscript. Olfa Bahri, Agnes Marchio and, Ines Dhifallah critically revised the manuscript.



**Conflict of Interests:** The authors declare that they have no financial conflict of interest with regard to the data contained in the manuscript.

**Ethical Approval:** Investigations were approved by Ethics Committee of Tunisian Ministry of Health.

**Funding/Support:** This work was supported by the French Ligue Nationale Contre le Cancer (Equipe Labelisee d'Anne Dejean) and the "Tunisian secretariat for Scientific Research and Technology" (SERST, contract: LR1ISPO9).

**Patient Consent:** Informed consent was obtained from each patient enrolled in the study.

## References

1. J. Ferlay I, Soerjomataram M, Ervik R, Dikshit S, Eser C, Mathers M, et al. *GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base No. 11*. Lyon, France: International Agency for Research on Cancer; 2013.
2. Mokdad AH, Jaber S, Aziz MI, AlBuhairan F, AlGhaithi A, AlHamad NM, et al. The state of health in the Arab world, 1990-2010: An analysis of the burden of diseases, injuries, and risk factors. *Lancet*. 2014;**383**(9914):309-20. doi: [10.1016/S0140-6736\(13\)62189-3](https://doi.org/10.1016/S0140-6736(13)62189-3). [PubMed: [24452042](https://pubmed.ncbi.nlm.nih.gov/24452042/)].
3. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. *Trans R Soc Trop Med Hyg*. 1997;**91**(1):11-4. doi: [10.1016/S0035-9203\(97\)90374-6](https://doi.org/10.1016/S0035-9203(97)90374-6). [PubMed: [9093616](https://pubmed.ncbi.nlm.nih.gov/9093616/)].
4. Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K. Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. *J Med Virol*. 2005;**76**(2):185-93. doi: [10.1002/jmv.20342](https://doi.org/10.1002/jmv.20342). [PubMed: [15834884](https://pubmed.ncbi.nlm.nih.gov/15834884/)].
5. Ben Slama Trabelsi A, Ksiaz M, Souguir A, Issaoui D, Sriha B, Ajmi S. [Hepatic steatosis in chronic hepatitis B: Prevalence, risk factors, and impact on fibrosis and therapeutic response]. *Tunis Med*. 2013;**91**(7):431-4. French. [PubMed: [24008872](https://pubmed.ncbi.nlm.nih.gov/24008872/)].
6. Hadidane R, Roger-Regnault C, Bouattour H, Ellouze F, Bacha H, Creppy EE, et al. Correlation between alimentary mycotoxin contamination and specific diseases. *Hum Toxicol*. 1985;**4**(5):491-501. doi: [10.1177/096032718500400505](https://doi.org/10.1177/096032718500400505). [PubMed: [2997022](https://pubmed.ncbi.nlm.nih.gov/2997022/)].
7. Abbes S, Salah-Abbes JB, Bouraoui Y, Oueslati S, Oueslati R. Natural occurrence of aflatoxins (B(1) and M(1)) in feed, plasma and raw milk of lactating dairy cows in Beja, Tunisia, using ELISA. *Food Addit Contam Part B Surveill*. 2012;**5**(1):11-5. doi: [10.1080/19393210.2011.640756](https://doi.org/10.1080/19393210.2011.640756). [PubMed: [24779689](https://pubmed.ncbi.nlm.nih.gov/24779689/)].
8. Oueslati S, Romero-Gonzalez R, Lasram S, Frenich AG, Vidal JL. Multi-mycotoxin determination in cereals and derived products marketed in Tunisia using ultra-high performance liquid chromatography coupled to triple quadrupole mass spectrometry. *Food Chem Toxicol*. 2012;**50**(7):2376-81. doi: [10.1016/j.fct.2012.04.036](https://doi.org/10.1016/j.fct.2012.04.036). [PubMed: [22579994](https://pubmed.ncbi.nlm.nih.gov/22579994/)].
9. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. *Mutat Res*. 2007;**635**(2-3):105-17. doi: [10.1016/j.mrrev.2006.11.002](https://doi.org/10.1016/j.mrrev.2006.11.002). [PubMed: [17257890](https://pubmed.ncbi.nlm.nih.gov/17257890/)].
10. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. *Lancet*. 1991;**338**(8779):1356-9. doi: [10.1016/0140-6736\(91\)92236-U](https://doi.org/10.1016/0140-6736(91)92236-U). [PubMed: [1682737](https://pubmed.ncbi.nlm.nih.gov/1682737/)].
11. Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. *Cancer Lett*. 2009;**286**(1):29-37. doi: [10.1016/j.canlet.2009.02.057](https://doi.org/10.1016/j.canlet.2009.02.057). [PubMed: [19376640](https://pubmed.ncbi.nlm.nih.gov/19376640/)].
12. Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. *Clin Res Hepatol Gastroenterol*. 2016;**40**(1):9-14. doi: [10.1016/j.clinre.2015.07.006](https://doi.org/10.1016/j.clinre.2015.07.006). [PubMed: [26336998](https://pubmed.ncbi.nlm.nih.gov/26336998/)].
13. Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. *Nucleic Acids Res*. 2012;**40**(11). e82. doi: [10.1093/nar/gks203](https://doi.org/10.1093/nar/gks203). [PubMed: [22373922](https://pubmed.ncbi.nlm.nih.gov/22373922/)]. [PubMed Central: [PMC3367212](https://pubmed.ncbi.nlm.nih.gov/PMC3367212/)].
14. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. *Clin Chem*. 2013;**59**(12):1722-31. doi: [10.1373/clinchem.2013.206359](https://doi.org/10.1373/clinchem.2013.206359). [PubMed: [23938455](https://pubmed.ncbi.nlm.nih.gov/23938455/)].
15. Debrand E, Lykoudi A, Bradshaw E, Allen SK. A non-invasive droplet digital PCR (ddPCR) assay to detect paternal CFTR mutations in the cell-free fetal DNA (cffDNA) of three pregnancies at risk of cystic fibrosis via compound heterozygosity. *PLoS One*. 2015;**10**(11). e0142729. doi: [10.1371/journal.pone.0142729](https://doi.org/10.1371/journal.pone.0142729). [PubMed: [26561302](https://pubmed.ncbi.nlm.nih.gov/26561302/)]. [PubMed Central: [PMC4641687](https://pubmed.ncbi.nlm.nih.gov/PMC4641687/)].
16. Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, et al. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. *Exp Ther Med*. 2015;**9**(4):1383-8. doi: [10.3892/etm.2015.2221](https://doi.org/10.3892/etm.2015.2221). [PubMed: [25780439](https://pubmed.ncbi.nlm.nih.gov/25780439/)]. [PubMed Central: [PMC4353752](https://pubmed.ncbi.nlm.nih.gov/PMC4353752/)].
17. Tang H, Cai Q, Li H, Hu P. Comparison of droplet digital PCR to real-time PCR for quantification of hepatitis B virus DNA. *Biosci Biotechnol Biochem*. 2016:1-6. doi: [10.1080/09168451.2016.1196576](https://doi.org/10.1080/09168451.2016.1196576). [PubMed: [27310131](https://pubmed.ncbi.nlm.nih.gov/27310131/)].
18. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: Results from a nationwide survey. *J Viral Hepat*. 2012;**19**(8):560-7. doi: [10.1111/j.1365-2893.2011.01576.x](https://doi.org/10.1111/j.1365-2893.2011.01576.x). [PubMed: [22762140](https://pubmed.ncbi.nlm.nih.gov/22762140/)].
19. Ezzikouri S, Pineau P, Benjelloun S. Hepatitis B virus in the Maghreb region: From epidemiology to prospective research. *Liver Int*. 2013;**33**(6):811-9. doi: [10.1111/liv.12135](https://doi.org/10.1111/liv.12135). [PubMed: [23530901](https://pubmed.ncbi.nlm.nih.gov/23530901/)].
20. Ezzikouri S, Pineau P, Benjelloun S. Hepatitis C virus infection in the Maghreb region. *J Med Virol*. 2013;**85**(9):1542-9. doi: [10.1002/jmv.23643](https://doi.org/10.1002/jmv.23643). [PubMed: [23780703](https://pubmed.ncbi.nlm.nih.gov/23780703/)].
21. Musaiger AO. Overweight and obesity in eastern mediterranean region: Prevalence and possible causes. *J Obes*. 2011;**2011**:407237. doi: [10.1155/2011/407237](https://doi.org/10.1155/2011/407237). [PubMed: [21941635](https://pubmed.ncbi.nlm.nih.gov/21941635/)]. [PubMed Central: [PMC3175401](https://pubmed.ncbi.nlm.nih.gov/PMC3175401/)].
22. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. *Liver Transpl*. 2004;**10**(2 Suppl 1):S69-73. doi: [10.1002/lt.20033](https://doi.org/10.1002/lt.20033). [PubMed: [14762843](https://pubmed.ncbi.nlm.nih.gov/14762843/)].
23. Ratzluy V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology*. 2002;**35**(6):1485-93. doi: [10.1053/jhep.2002.33324](https://doi.org/10.1053/jhep.2002.33324). [PubMed: [12029634](https://pubmed.ncbi.nlm.nih.gov/12029634/)].
24. Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. *Cancer Epidemiol*. 2015;**39**(3):284-90. doi: [10.1016/j.canep.2015.04.006](https://doi.org/10.1016/j.canep.2015.04.006). [PubMed: [25922178](https://pubmed.ncbi.nlm.nih.gov/25922178/)].
25. Hefaidh R, Ennaifer R, Romdhane H, Ben Nejma H, Arfa N, Belhadj N, et al. Gender difference in patients with hepatocellular carcinoma. *Tunis Med*. 2013;**91**(8-9):505-8. [PubMed: [24227507](https://pubmed.ncbi.nlm.nih.gov/24227507/)].
26. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. *Nat Genet*. 2014;**46**(12):1267-73. doi: [10.1038/ng.3126](https://doi.org/10.1038/ng.3126). [PubMed: [25362482](https://pubmed.ncbi.nlm.nih.gov/25362482/)].

27. Miller JD. Changing patterns of fungal toxins in crops: Challenges for analysts. *J AOAC Int.* 2016;**99**(4):837–41. doi: [10.5740/jaoacint.16-0110](https://doi.org/10.5740/jaoacint.16-0110). [PubMed: [27455926](https://pubmed.ncbi.nlm.nih.gov/27455926/)].
28. Uhlig S, Eriksen GS, Hofgaard IS, Krska R, Beltran E, Sulyok M. Faces of a changing climate: Semi-quantitative multi-mycotoxin analysis of grain grown in exceptional climatic conditions in Norway. *Toxins (Basel)*. 2013;**5**(10):1682–97. doi: [10.3390/toxins5101682](https://doi.org/10.3390/toxins5101682). [PubMed: [24084167](https://pubmed.ncbi.nlm.nih.gov/24084167/)]. [PubMed Central: [PMC3813906](https://pubmed.ncbi.nlm.nih.gov/PMC3813906/)].
29. Boutrif E, Jemmali M, Campbell AD, Pohland AE. Aflatoxin in Tunisian foods and foodstuffs. *Ann Nutr Aliment.* 1977;**31**(4-6):431–4. [PubMed: [613907](https://pubmed.ncbi.nlm.nih.gov/613907/)].
30. Boutrif E, Jemmali M, Pohland AE, Campbell AD. Aflatoxin in Tunisian aleppo pine nuts. *J Assoc Off Anal Chem.* 1977;**60**(3):747–8. [PubMed: [870495](https://pubmed.ncbi.nlm.nih.gov/870495/)].
31. Ben Rejeb I, Arduini F, Arvinte A, Amine A, Gargouri M, Micheli L, et al. Development of a bio-electrochemical assay for AFB1 detection in olive oil. *Biosens Bioelectron.* 2009;**24**(7):1962–8. doi: [10.1016/j.bios.2008.10.002](https://doi.org/10.1016/j.bios.2008.10.002). [PubMed: [19026530](https://pubmed.ncbi.nlm.nih.gov/19026530/)].
32. Bensassi F, Rhouma A, Ghrab M, Bacha H, Rabeh Hajlaoui M. Evaluation of cultivar susceptibility and storage periods towards aflatoxin B1 contamination on pistachio nuts. *Mycotoxin Res.* 2010;**26**(3):199–203. doi: [10.1007/s12550-010-0054-7](https://doi.org/10.1007/s12550-010-0054-7). [PubMed: [23605384](https://pubmed.ncbi.nlm.nih.gov/23605384/)].
33. Ghali R, Khlifa KH, Ghorbel H, Maaroufi K, Hedilli A. Aflatoxin determination in commonly consumed foods in Tunisia. *J Sci Food Agric.* 2010;**90**(14):2347–51. doi: [10.1002/jsfa.4069](https://doi.org/10.1002/jsfa.4069). [PubMed: [20812375](https://pubmed.ncbi.nlm.nih.gov/20812375/)].
34. Jedidi I, Cruz A, Gonzalez-Jaen MT, Said S. Aflatoxins and ochratoxin A and their *Aspergillus* causal species in Tunisian cereals. *Food Addit Contam Part B Surveill.* 2017;**10**(1):51–8. doi: [10.1080/19393210.2016.1247917](https://doi.org/10.1080/19393210.2016.1247917). [PubMed: [27735214](https://pubmed.ncbi.nlm.nih.gov/27735214/)].
35. Fernández-Cruz ML, Mansilla ML, Tadeo JL. Mycotoxins in fruits and their processed products: Analysis, occurrence and health implications. *J Adv Res.* 2010;**1**(2):113–22. doi: [10.1016/j.jare.2010.03.002](https://doi.org/10.1016/j.jare.2010.03.002).
36. Ozkan A, Bindak R, Erkmén O. Aflatoxin B(1) and aflatoxins in ground red chilli pepper after drying. *Food Addit Contam Part B Surveill.* 2015;**8**(3):227–33. doi: [10.1080/19393210.2015.1063014](https://doi.org/10.1080/19393210.2015.1063014). [PubMed: [26099014](https://pubmed.ncbi.nlm.nih.gov/26099014/)].
37. Hosny G, Farahat N, Tayel H, Hainaut P. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. *Cancer Lett.* 2008;**264**(2):201–8. doi: [10.1016/j.canlet.2008.01.031](https://doi.org/10.1016/j.canlet.2008.01.031). [PubMed: [18313840](https://pubmed.ncbi.nlm.nih.gov/18313840/)].
38. El-Din HG, Ghafar NA, Saad NE, Aziz M, Rasheed D, Hassan EM. Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma. *Arch Med Sci.* 2010;**6**(3):348–55. doi: [10.5114/aoms.2010.14254](https://doi.org/10.5114/aoms.2010.14254). [PubMed: [22371770](https://pubmed.ncbi.nlm.nih.gov/22371770/)]. [PubMed Central: [PMC3282511](https://pubmed.ncbi.nlm.nih.gov/PMC3282511/)].
39. Traore F, Gormally E, Villar S, Friesen MD, Groopman JD, Vernet G, et al. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. *BMC Infect Dis.* 2015;**15**:180. doi: [10.1186/s12879-015-0916-x](https://doi.org/10.1186/s12879-015-0916-x). [PubMed: [25886382](https://pubmed.ncbi.nlm.nih.gov/25886382/)]. [PubMed Central: [PMC4403772](https://pubmed.ncbi.nlm.nih.gov/PMC4403772/)].
40. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: A review of toxicology, exposure, potential health consequences, and interventions. *Am J Clin Nutr.* 2004;**80**(5):1106–22. doi: [10.1093/ajcn/80.5.1106](https://doi.org/10.1093/ajcn/80.5.1106). [PubMed: [15531656](https://pubmed.ncbi.nlm.nih.gov/15531656/)].
41. Khlangwiset P, Shephard GS, Wu F. Aflatoxins and growth impairment: A review. *Crit Rev Toxicol.* 2011;**41**(9):740–55. doi: [10.3109/10408444.2011.575766](https://doi.org/10.3109/10408444.2011.575766). [PubMed: [21711088](https://pubmed.ncbi.nlm.nih.gov/21711088/)].
42. Lombard MJ. Mycotoxin exposure and infant and young child growth in Africa: What do we know? *Ann Nutr Metab.* 2014;**64** Suppl 2:42–52. doi: [10.1159/000365126](https://doi.org/10.1159/000365126). [PubMed: [25341872](https://pubmed.ncbi.nlm.nih.gov/25341872/)].